Israel just announced big news for its legal cannabis industry that I believe will create an awesome investment opportunity right around the corner. But before I reveal this new opportunity, let me back up a bit and tell you how Israel became a leader in the global cannabis industry.
Israel is a pioneer in medical cannabis research.
The Israeli professor Raphael Mechoulam from the Hebrew University is considered the “father of medical cannabis.”
Mechoulam began studying medical cannabis in the 1960s and would go on to become the first scientist in the world to identify a number of compounds in cannabis, including THC, the compound that gets people stoned.
Since then Israel’s cannabis industry has continued to expand.
In 1992 it became one of the first countries in the world to legalize medical cannabis.
More recently, according to a report from Reuters, there are more than 120 clinical cannabis trials in Israel at the beginning of 2017, more than any other country.
In the last year outside countries and companies have invested $100 million to license Israeli medical cannabis patents.
In March of 2017, Israel voted to decriminalize cannabis.
However, these milestones pale in comparison to the most recent breakthrough.
Israel’s Cannabis Industry Has Scored Another Big Win
Israel’s cannabis industry just took another big step forward.
The Israeli Ministry of Agriculture has reclassified growing medical cannabis into the farming sector. The Ministries of Health and Finance has also legalized the export of medical cannabis.
This is a big breakthrough for Israel’s cannabis industry.
Despite Israel’s prominence in cannabis research, it was still illegal to grow and export cannabis in Israel.
This reclassification changes that.
Cannabis farmers can now qualify for government aid, grants and water rations just like other farmers.
Become a Cannabis Stock Trades member to get exclusive analysis, trade alerts, Q&A, and more! Join Cannabis Stock Trades Today!
Most important to us, the reclassification sets the stage for a new billion-dollar industry. Analysts are predicting Israel could quickly ramp up to $1 billion in annual cannabis exports.
According to a government report, more than 500 Israeli companies have already submitted applications for licenses to grow, manufacture, and export cannabis products.
Landing one of these permits is like winning the lottery.
The latest word I have seen is that 37 companies have been granted a cultivation license.
Breath of Life is one lucky winner.
This Israeli company owns one million square feet of potential cultivation fields, a 35,000-square-foot production plant and 30,000 square feet of grow rooms and labs.
When the build-out is finished, BOL expects to be one of the largest growers in the world producing more than 175,000 pounds of cannabis per year.
What is the best way to profit from this news?
As it stands, BOL and the other recipients of these cannabis cultivation permits are still privately owned. That means we can’t buy shares on a stock exchange.
However, I expect that to change sooner than later. And when it does, I think it will present an awesome investment opportunity.
In fact, It reminds me of exactly how the Canadian cannabis market has developed.
The first companies that received cultivation permits have seen their share prices skyrocket.
For example, Canopy Growth Corp (TWMJF) and Aphria (APHQF) were two of the first companies in Canada to receive cultivation permits and go public. In just the last two years these stocks have posted huge gains. Take a look below.
For the time being – the best way to profit from Israel’s medical cannabis industry is through its biotech companies.
Here are two early industry leaders to check out.
Cannabix (CNBX) is a young Israeli cannabis biotech that specializes in cannabis-based cancer treatments. The company has a license from the Israeli Ministry of Health for its work in both scientific and clinical research.
OWC Pharmaceutical Research (OWCP) is another early stage Israeli cannabis biotech. OWC is conducting cannabis research and clinical trials and developing proprietary cannabis technology and delivery systems. The goal of this research is two-fold. First, to develop branded drugs and medicine. And secondly, to license its proprietary technology and research to other pharmaceutical and cannabis companies.
I wrote about OWCP in April if you would like to take a second look.
I will be keeping a close eye on the Israeli cannabis sector. If I see a great opportunity, you will be the first to know.